Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 3/20 | 0.67 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.67 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.67 |
| ▸ | HRH1 | P35367 | 1/20 | 0.67 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.63 |
| ▸ | RECQL | P46063 | 1/20 | 0.63 |
| ▸ | SLC25A20 | O43772 | 3/20 | 0.54 |
| ▸ | TSHR | P16473 | 3/20 | 0.54 |
| ▸ | TP53 | P04637 | 2/20 | 0.54 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.54 |
| ▸ | SLC6A5 | Q9Y345 | 2/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.54 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.54 |
| ▸ | MAPT | P10636 | 1/20 | 0.54 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.54 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.54 |
| ▸ | THPO | P40225 | 1/20 | 0.54 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.54 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.54 |
| ▸ | SLC22A16 | Q86VW1 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17416718 | 1.00 | MEN1 (0.67) | MEN1KMT2ACYP1A2HRH1CYP2C19 | |
| SCHEMBL3445036 | 1.00 | MEN1 (0.67) | MEN1KMT2ACYP1A2HRH1CYP2C19 | |
| SCHEMBL2565442 | 0.88 | MEN1 (0.69) | MEN1KMT2ACYP1A2HRH1CYP2C19 | |
| SCHEMBL677165 | 0.88 | MEN1 (0.69) | MEN1KMT2ACYP1A2HRH1CYP2C19 | |
| SCHEMBL234697 | 0.88 | MEN1 (0.69) | MEN1KMT2ACYP1A2HRH1CYP2C19 | |
| SCHEMBL17164649 | 0.87 | MEN1 (0.63) | MEN1KMT2ACYP1A2HRH1CYP2C19 | |
| SCHEMBL288256 | 0.87 | MEN1 (0.63) | MEN1KMT2ACYP1A2HRH1CYP2C19 | |
| Hydrochloric Acid SCHEMBL8752465 | 0.86 | MEN1 (0.67) | MEN1KMT2ACYP1A2HRH1CYP2C19 | |
| Bromide SCHEMBL2995963 | 0.86 | MEN1 (0.67) | MEN1KMT2ACYP1A2HRH1CYP2C19 | |
| SCHEMBL10899938 | 0.85 | MEN1 (0.65) | MEN1KMT2ACYP1A2HRH1CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 61 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240066001-A1 | METHODS AND COMPOSITIONS FOR TREATING OBESITY, PREVENTING WEIGHT GAIN, PROMOTING WEIGHT LOSS, PROMOTING SLIMMING, OR TREATING OR PREVENTING THE DEVELOPMENT OF DIABETES | SILTI AG (CH) | 2024-02-29 | — | — | US | claimed |
| EP-3164125-B1 | METHODS AND COMPOSITIONS FOR TREATING OBESITY, PREVENTING WEIGHT GAIN, PROMOTING WEIGHT LOSS, PROMOTING SLIMMING, OR TREATING OR PREVENTING THE DEVELOPMENT OF DIABETES | NAN GLOBAL LLC (US) | 2023-09-06 | — | — | EP | claimed |
| CN-113387836-A | Methods and compositions for treating obesity, preventing weight gain, promoting weight loss, or treating or preventing the development of diabetes | NAN全球有限责任公司 | 2021-09-14 | — | — | CN | claimed |
| US-20210186918-A1 | METHODS AND COMPOSITIONS FOR TREATING OBESITY, PREVENTING WEIGHT GAIN, PROMOTING WEIGHT LOSS, PROMOTING SLIMMING, OR TREATING OR PREVENTING THE DEVELOPMENT OF DIABETES | MOLECULE X LLC | 2021-06-24 | — | — | US | claimed |
| EP-2190402-B2 | BIOTIN AND SILICA IN DYE COMPOSITIONS | HENKEL AG & CO KGAA (DE) | 2018-10-17 | — | — | EP | claimed |
| EP-3164125-A2 | METHODS AND COMPOSITIONS FOR TREATING OBESITY, PREVENTING WEIGHT GAIN, PROMOTING WEIGHT LOSS, PROMOTING SLIMMING, OR TREATING OR PREVENTING THE DEVELOPMENT OF DIABETES | Nan Global, LLC (US) | 2017-05-10 | — | — | EP | claimed |
| EP-2190402-B1 | BIOTIN AND SILICA IN DYE COMPOSITIONS | HENKEL AG & CO KGAA (DE) | 2016-01-13 | — | — | EP | claimed |
| WO-2016004363-A2 | METHODS AND COMPOSITIONS FOR TREATING OBESITY, PREVENTING WEIGHT GAIN, PROMOTING WEIGHT LOSS, PROMOTING SLIMMING, OR TREATING OR PREVENTING THE DEVELOPMENT OF DIABETES | NAN Global, LLC (US) | 2016-01-07 | — | — | WO | claimed |
| US-20160000745-A1 | METHODS AND COMPOSITIONS FOR TREATING OBESITY, PREVENTING WEIGHT GAIN, PROMOTING WEIGHT LOSS, PROMOTING SLIMMING, OR TREATING OR PREVENTING THE DEVELOPMENT OF DIABETES | MOLECULE X LLC | 2016-01-07 | — | — | US | claimed |
| EP-1218001-B1 | ULTRAFINE L-CARNITINE, METHODS OF PREPARING THE SAME, COMPOSITIONS CONTAINING THE SAME, AND METHODS OF USING THE SAME | SIGMA TAU HEALTHSCIENCE SPA (IT) | 2008-12-31 | — | — | EP | claimed |
| CN-101120935-A | Ultrafine l-carnitine, methods of preparing the same, compositions containing the same, and methods of using the same | SIGMA TAU HEALTHSCIENCE SPA (IT) | 2008-02-13 | — | — | CN | claimed |
| US-7303765-B2 | Ultrafine-L-carnitine, methods of preparing the same, compositions containing the same, and methods of using the same | SIGMA-TAU HEALTHSCIENCE S.P.A. (IT) | 2007-12-04 | — | — | US | claimed |
| US-20050124558-A1 | Ultrafine-L-carnitine, methods of preparing the same, compositions containing the same, and methods of using the same | SIGMA-TAU HEALTHSCIENCE S.P.A. (IT) | 2005-06-09 | — | — | US | claimed |
| EP-1218001-A4 | ULTRAFINE L-CARNITINE, METHODS OF PREPARING THE SAME, COMPOSITIONS CONTAINING THE SAME, AND METHODS OF USING THE SAME | SIGMA TAU HEALTHSCIENCE SPA (IT) | 2005-05-18 | — | — | EP | claimed |
| CN-1399549-A | Ultra-fine L-carnitine, methods of making, compositions containing, and methods of using | SIGMA TAU HEALTHSCIENCE SPA (IT) | 2003-02-26 | — | — | CN | claimed |
| US-20020111383-A1 | Ultrafine L-carnitine, methods of preparing the same, compositions containing the same, and methods of using the same | SIGMA-TAU HEALTHSCIENCE S.P.A. (IT) | 2002-08-15 | — | — | US | claimed |
| EP-1218001-A1 | ULTRAFINE L-CARNITINE, METHODS OF PREPARING THE SAME, COMPOSITIONS CONTAINING THE SAME, AND METHODS OF USING THE SAME | Sigma-Tau Healthscience S.p.A. (IT) | 2002-07-03 | — | — | EP | claimed |
| WO-2001017525-A1 | ULTRAFINE L-CARNITINE, METHODS OF PREPARING THE SAME, COMPOSITIONS CONTAINING THE SAME, AND METHODS OF USING THE SAME | SIGMA-TAU HEALTHSCUIENCE S.P.A (IT) | 2001-03-15 | — | — | WO | claimed |
| US-12390406-B2 | Process for treating keratin fibers using a composition comprising a carnitine salt or carnitine derivative salt comprising an aliphatic dicarboxylic acid anion | L'OREAL (FR) | 2025-08-19 | — | — | US | disclosed |
| WO-2000074483-A1 | IMPROVED STORAGE AND MAINTENANCE OF BLOOD PRODUCTS INCLUDING RED BLOOD CELLS AND PLATELETS | SIGMA-TAU INDUSTRIE FARMACEUTICHE RIUNITE S.P.A. (IT) | 2000-12-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210186918-A1 | METHODS AND COMPOSITIONS FOR TREATING OBESITY, PREVENTING WEIGHT GAIN, PROMOTING WEIGHT LOSS, PROMOTING SLIMMING, OR TREATING OR PREVENTING THE DEVELOPMENT OF DIABETES | GPR119, CPT1B, CPT2 | MEN1 3979/4885KMT2A 1054/4885CYP1A2 4593/4885 |
| US-20240066001-A1 | METHODS AND COMPOSITIONS FOR TREATING OBESITY, PREVENTING WEIGHT GAIN, PROMOTING WEIGHT LOSS, PROMOTING SLIMMING, OR TREATING OR PREVENTING THE DEVELOPMENT OF DIABETES | GPR119, CPT1B, CPT2 | MEN1 3979/4885KMT2A 1054/4885CYP1A2 4593/4885 |
| US-12390406-B2 | Process for treating keratin fibers using a composition comprising a carnitine salt or carnitine derivative salt comprising an aliphatic dicarboxylic acid anion | KRT18, CRAT, CPT1B | MEN1 3498/4885KMT2A 564/4885CYP1A2 4346/4885 |
| US-20160000745-A1 | METHODS AND COMPOSITIONS FOR TREATING OBESITY, PREVENTING WEIGHT GAIN, PROMOTING WEIGHT LOSS, PROMOTING SLIMMING, OR TREATING OR PREVENTING THE DEVELOPMENT OF DIABETES | GPR119, CPT1B, CPT2 | MEN1 3979/4885KMT2A 1054/4885CYP1A2 4593/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.